Treating high triglyceride levels reduces the risk of heart disease
the verdict
CONTESTED
the evidence cuts both ways
confidence 22/100
While observational and genetic studies link high triglycerides to cardiovascular disease, clinical trials testing triglyceride-lowering therapies have yielded inconsistent results regarding cardiovascular risk reduction.
The evidence we hold leans evenly split
How this was weighed
official record 3x · fact-check 2x · hedged 1x · crowd & reference 1x
Do triglyceride-lowering drugs decrease risk of cardiovascul · peer-reviewed · supports · weight 1.3 · 2017
Pemafibrate and other triglyceride-lowering therapies to red · peer-reviewed · supports · weight 1.05 · 2024
2025: The year in cardiovascular disease – the year of trigl · peer-reviewed · supports · weight 1.05 · 2025
Pemafibrate and other triglyceride-lowering therapies to red · peer-reviewed · refutes · weight 1.05 · 2024
Lipid management in type 2 diabetes and non-HDL-cholesterol: · peer-reviewed · refutes · weight 1.05 · 2026
Triglyceride-Rich Lipoproteins and ASCVD: Evidence for Causa · peer-reviewed · refutes · weight 1 · 2026
Rethinking triglycerides in the management of ASCVD. · peer-reviewed · refutes · weight 1 · 2026
Evidence for · 3
Do triglyceride-lowering drugs decrease risk of cardiovascular disease?
2017 · cited by 12
Subgroup and observational data suggest that lowering triglycerides and remnant lipoproteins is associated with reduced cardiovascular risk.
Evidence against · 4
Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease
2024 · cited by 6
Several prominent clinical trials, such as STRENGTH and PROMINENT, failed to show that lowering triglycerides translated to reduced cardiovascular events.
See more details
More for · 2
Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease
2024 · cited by 6
The REDUCE-IT trial demonstrated significant cardiovascular risk reduction using icosapent ethyl in hypertriglyceridemic patients.
2025: The year in cardiovascular disease – the year of triglyceride lowering therapies. Can we effectively reduce triglyceride-related residual cardiovascular disease and pancreatitis risk?
2025 · cited by 2
Certain targeted therapies like icosapent ethyl and fenofibrate are endorsed in guidelines to address residual cardiovascular risk in high-risk patients with elevated triglycerides.
More against · 3
Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins.
2026 · cited by 1
The impact of conventional triglyceride-lowering therapies like omega-3 fatty acids and fibrates on cardiovascular outcomes remains uncertain.
Triglyceride-Rich Lipoproteins and ASCVD: Evidence for Causality and Challenges in Therapeutic Translation.
2026 · cited by 0
Therapeutic translation has been inconsistent, and agents like icosapent ethyl may reduce cardiovascular events through mechanisms independent of pure triglyceride lowering.
Rethinking triglycerides in the management of ASCVD.
2026 · cited by 0
Reducing triglyceride concentrations alone does not consistently decrease cardiovascular events, indicating they act more as markers of remnant particle burden rather than direct therapeutic targets.